Tiziana Life Sciences pursuing development of intranasal foralumab for Long COVID treatment
News release
by
Tiziana Life Sciences PLC
New York
|
April 17, 2023 05:53 AM Eastern Daylight Time
Tiziana Life Sciences chief medical officer Dr Matthew Davis joins Proactive's Natalie Stoberman to explain how the company is pursuing the development of intranasal foralumab for the treatment of Long COVID.
Davis says Tiziana intends to enter into a three-month Phase 2a placebo-controlled clinical trial to research how foralumab’s well-established role in de-activating microglia cells could treat or reduce the symptoms of Long COVID.
Contact Details
Proactive Investors
+1 347-449-0879
